Outcome of patients with primary hepatic venous obstruction treated with anticoagulants alone
Tóm tắt
Outcome of patients with hepatic venous outflow tract obstruction (HVOTO) has improved with newer treatments, including anticoagulants, radiological interventions and liver transplant. In India, however, liver transplant and radiological interventions are costly and have limited availability. Hence, patients often opt for anticoagulation alone. We followed up a group of such patients to determine the clinical outcome with such treatment. Consecutive patients with HVOTO, treated with oral anticoagulation and supportive medical therapy but no radiological or surgical intervention, were followed up for at least 12 months. Diagnosis of HVOTO was based on color Doppler, and either angiography or magnetic resonance venography. Warfarin dose was adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0. Patients with secondary HVOTO and those with baseline INR ≥2.0 were excluded. Response was defined as absence of ascites and/or encephalopathy, normal AST/ALT, bilirubin <1.5 mg/dL, and no portal hypertension related bleed after starting therapy. Of 43 patients (mean [SD] age=28.7 [8.4] years; 20 men), 26 (61%) had a response during a median follow up of 23 (range 15–33) months. The response first appeared within 2 months of the start of treatment in 18 patients and between 2 and 5 months from the start of treatment in eight patients. Seven patients died of progressive liver failure (6 patients) or GI bleed (1 patient). Nine patients had anticoagulation-related complications. On univariate analysis, short duration of symptoms, high serum albumin, low baseline INR, and low baseline Child-Pugh’s (CP) or Clichy scores predicted response. Presence of hepatic encephalopathy, portal vein thrombosis, obstruction of all hepatic veins, low albumin, high INR, high serum bilirubin, high baseline CP score, Murad score and adverse Clichy index were associated with higher mortality rate. However, on multivariate analysis, only low CP score was associated with response, and no factor was found to predict death. More than half of patients with HVOTO show response with only supportive medical therapy and anticoagulants. This occurs more often in patients with low CP score. Some patients may have delayed response.
Tài liệu tham khảo
Hadengue A, Poliquin M, Vilgrain V, et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology 1994;106:1042–1047.
Plessier A, Sibert A, Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 2006;44:1308–1316.
Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology 2008;47:1384–1393.
Bhattacharyya M, Makharia G, Kannan M, et al. Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol 2004;121:844–847.
Mohanty D, Shetty S, Ghosh K, et al. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology 2001;34:666–670.
Kumar SI, Kumar A, Srivastava S, et al. Low frequency of factor V Leiden and prothrombin G20210A mutations in patients with hepatic venous outflow tract obstruction in northern India: a case-control study. Indian J Gastroenterol 2005;24:211–215.
Shyamkumar NK, Mammen T, Chandramohan A, et al. Pattern of hepatic venous outflow obstruction in Budd Chiari syndrome - an institutional experience. Indian Association for Study of the Liver, Vellore, 2007 (Abstract L-42A).
Jain P, Rai RR, Nijhawan S, et al. Budd Chiari syndrome associated with portal vein and superior mesenteric vein thrombosis. Indian Association for Study of the Liver, Vellore, 2007 (Abstract L-44).
Shukla A, Rathod K, Bapat MR, et al. Profile of hepatic venous outflow obstruction in Mumbai. Indian Association for Study of the Liver, Vellore, 2007 (Abstract L-43).
Murad SD, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004;39:500–508.
Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology 1999;30:84–89.
Ahn S, Yellin A, Shong FC, et al. Selective surgical therapy of the Budd-Chiari syndrome provides superior survivor rates than conservative medical management. J Vasc Surg 1987;5:28–37.
McCarthy PM, Von Heerdon JA, Adson MA, et al. The Budd-Chiari syndrome and surgical management in 30 patients. Arch Surg 1984;120:657–662.
Min AD, Atillasoy EO, Schwartz ME, et al. Reassessing the role of medical therapy in the management of hepatic vein thrombosis. Liver Transplant Surg 1997;3:423–429.
Garcia-Pagan JC, Hedtmann M, Raffa S, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostic factors in 124 patients. Gastroenterology 2008;135:808–815.
Amarapurkar DN, Punamiya SJ, Patel ND. Changing spectrum of Budd-Chiari syndrome in India with special reference to non-surgical treatment. World J Gastroenterol 2008;14:278–285.